EuropeFX has recently expanded its own offering to include a basket of seven Pharma Stocks.
FM
2020 has been defined by the outbreak of Covid-19, which according to many health experts has yet to even reach its peak.
To date, a vaccine has not yet been created to combat the virus, though pharmaceutical companies worldwide are aggressively pursuing one.
This has made investing in pharmaceutical stocks one of the most attractive options in 2020, given the huge potential upside of rolling out the first vaccine for Covid-19.
EuropeFX is clearly cognizant of this demand, having recently expanded its own offering to include a basket of Pharma Stocks.
The brokerage is now offering exposure into seven different pharmaceutical companies that are currently the frontrunners for a Covid-19 vaccine.
Why Now Could Be an Interesting Time to Invest in Pharma Stocks
Hundreds of thousands have died worldwide and the demand for a vaccine has never been higher. This has created an unprecedented demand, which could catapult a pharmaceutical’s valuation through the roof overnight.
Traditionally, pharmaceutical companies face long roads to inventing vaccines. Long before these get to the market, a vaccine has to pass multiple stages of trials to ensure its safety.
These are decreased, however, once the World Health Organization (WHO) has announced a pandemic, which is the case for Covid-19.
As a result, several pharmaceutical companies have seen an extraordinary level of speculative interest from investors during the trial stages of a vaccine.
Which Companies Could You Invest in?
EuropeFX now has seven pharmaceutical companies leading the race for a Covid-19 vaccine globally on offer. This includes the following companies:
Gilead Sciences Inc.
(NASDAQ:GILD)
A research-based biopharmaceutical company, Gilead Sciences, currently carries over twenty-five marketed treatments in the United States for HIV and Aids, Liver Diseases, Hematology and Oncology, Cardiovascular Disease and Inflammation and Respiratory Disease. Gilead is currently in Phase-3 trials for Remdesivir, a Covid-19 drug.
Merck KGaA
(NYSE:MRK)
Founded in Darmstadt, Germany, Merck & Co is active in sixty-six countries and with around 57,000 employees, the Company generated sales of €16.2 billion in 2019. The Company is active in all areas of pharmaceutical production and food safety and is heavily involved in the performance material sector for a broad and diverse range of industries.
Amgen Inc.
(NASDAQ:AMGN)
Founded in the United States in 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies. Amgen is currently focused on six therapeutic areas: cardiovascular disease, oncology, bone health, neuroscience, nephrology, and inflammation. The Company generated sales of $22.2 billion in 2019.
Dynavax Technologies Inc.
(NASDAQ:DVAX)
Dynavax Technologies Corporation develops and commercializes novel vaccines. The Company’s first commercial product, HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted], a hepatitis B vaccine for adults, is approved in the United States. 2019 saw product revenue of $34.6 million.
Biogen Inc.
(NASDAQ:BIIB)
Founded in Geneva, Switzerland, Biogen helped pioneer the biotechnology industry. A leader in the development of treatments for Multiple Sclerosis, Spinal Muscular Atrophy, and Alzheimer’s Disease, Biogen’s revenues in 2019 were over $14.3 billion, for a 4.5% increase in total revenues year over year.
Biotest Aktiengesellschaft
(XETRA:BIO3.DE)
Founded in Germany, Biotest markets different products in three therapeutic areas: clinical immunology, haematology, and intensive care medicine. The Company is active globally, with locations in Europe, South America, and the Russian Federation. 2019 saw revenues of over €419 million, and the Company embarked on an ambitious expansion program with investments of over €300 million planned for their Dreieich location with the creation of over 300 new jobs in the region.
Moderna, Inc
(NASDAQ:MRNA)
Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases.
Risk Warning: CFDs are complex instruments and carry a high risk of losing money quickly due to leverage. 78.94% of retail investor accounts lose money when trading CFDs with this provider. The information contained in this market overview should in no way be construed as investment advice and/or as a proposal and/or request for trading activities and financial transactions. The data contained in this market overview is not necessarily real-time or error-free. The data and prices on the material are not necessarily provided by a market or exchange, but by market makers, so that prices may not be accurate and may differ from the actual price in a particular market, meaning that prices are indicative and not suitable for trading purposes. There is no guarantee and/or prediction of future performance. EuropeFX, its affiliates, agents, directors or employees do not guarantee the accuracy or validity of any information or data provided and shall not be liable for any loss arising from any investment based thereon. Trading Forex/CFD's carries a high level of risk and may result in the loss of your entire investment. Forex/CFD's are leveraged products and therefore trading Forex/CFD's may not be suitable for all investors. It is recommended not to invest more money than you can afford to lose in order to avoid significant financial problems in case of losses. Please make sure that you define the maximum risk for yourself.
2020 has been defined by the outbreak of Covid-19, which according to many health experts has yet to even reach its peak.
To date, a vaccine has not yet been created to combat the virus, though pharmaceutical companies worldwide are aggressively pursuing one.
This has made investing in pharmaceutical stocks one of the most attractive options in 2020, given the huge potential upside of rolling out the first vaccine for Covid-19.
EuropeFX is clearly cognizant of this demand, having recently expanded its own offering to include a basket of Pharma Stocks.
The brokerage is now offering exposure into seven different pharmaceutical companies that are currently the frontrunners for a Covid-19 vaccine.
Why Now Could Be an Interesting Time to Invest in Pharma Stocks
Hundreds of thousands have died worldwide and the demand for a vaccine has never been higher. This has created an unprecedented demand, which could catapult a pharmaceutical’s valuation through the roof overnight.
Traditionally, pharmaceutical companies face long roads to inventing vaccines. Long before these get to the market, a vaccine has to pass multiple stages of trials to ensure its safety.
These are decreased, however, once the World Health Organization (WHO) has announced a pandemic, which is the case for Covid-19.
As a result, several pharmaceutical companies have seen an extraordinary level of speculative interest from investors during the trial stages of a vaccine.
Which Companies Could You Invest in?
EuropeFX now has seven pharmaceutical companies leading the race for a Covid-19 vaccine globally on offer. This includes the following companies:
Gilead Sciences Inc.
(NASDAQ:GILD)
A research-based biopharmaceutical company, Gilead Sciences, currently carries over twenty-five marketed treatments in the United States for HIV and Aids, Liver Diseases, Hematology and Oncology, Cardiovascular Disease and Inflammation and Respiratory Disease. Gilead is currently in Phase-3 trials for Remdesivir, a Covid-19 drug.
Merck KGaA
(NYSE:MRK)
Founded in Darmstadt, Germany, Merck & Co is active in sixty-six countries and with around 57,000 employees, the Company generated sales of €16.2 billion in 2019. The Company is active in all areas of pharmaceutical production and food safety and is heavily involved in the performance material sector for a broad and diverse range of industries.
Amgen Inc.
(NASDAQ:AMGN)
Founded in the United States in 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies. Amgen is currently focused on six therapeutic areas: cardiovascular disease, oncology, bone health, neuroscience, nephrology, and inflammation. The Company generated sales of $22.2 billion in 2019.
Dynavax Technologies Inc.
(NASDAQ:DVAX)
Dynavax Technologies Corporation develops and commercializes novel vaccines. The Company’s first commercial product, HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted], a hepatitis B vaccine for adults, is approved in the United States. 2019 saw product revenue of $34.6 million.
Biogen Inc.
(NASDAQ:BIIB)
Founded in Geneva, Switzerland, Biogen helped pioneer the biotechnology industry. A leader in the development of treatments for Multiple Sclerosis, Spinal Muscular Atrophy, and Alzheimer’s Disease, Biogen’s revenues in 2019 were over $14.3 billion, for a 4.5% increase in total revenues year over year.
Biotest Aktiengesellschaft
(XETRA:BIO3.DE)
Founded in Germany, Biotest markets different products in three therapeutic areas: clinical immunology, haematology, and intensive care medicine. The Company is active globally, with locations in Europe, South America, and the Russian Federation. 2019 saw revenues of over €419 million, and the Company embarked on an ambitious expansion program with investments of over €300 million planned for their Dreieich location with the creation of over 300 new jobs in the region.
Moderna, Inc
(NASDAQ:MRNA)
Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases.
Risk Warning: CFDs are complex instruments and carry a high risk of losing money quickly due to leverage. 78.94% of retail investor accounts lose money when trading CFDs with this provider. The information contained in this market overview should in no way be construed as investment advice and/or as a proposal and/or request for trading activities and financial transactions. The data contained in this market overview is not necessarily real-time or error-free. The data and prices on the material are not necessarily provided by a market or exchange, but by market makers, so that prices may not be accurate and may differ from the actual price in a particular market, meaning that prices are indicative and not suitable for trading purposes. There is no guarantee and/or prediction of future performance. EuropeFX, its affiliates, agents, directors or employees do not guarantee the accuracy or validity of any information or data provided and shall not be liable for any loss arising from any investment based thereon. Trading Forex/CFD's carries a high level of risk and may result in the loss of your entire investment. Forex/CFD's are leveraged products and therefore trading Forex/CFD's may not be suitable for all investors. It is recommended not to invest more money than you can afford to lose in order to avoid significant financial problems in case of losses. Please make sure that you define the maximum risk for yourself.
Beyond FX: What Match-Trader Is Bringing to Brokers at iFX EXPO International
Featured Videos
FM Daily Brief – 11 June 2026
FM Daily Brief – 11 June 2026
FM Daily Brief – 11 June 2026
FM Daily Brief – 11 June 2026
Today’s Thursday, the 11th of June 2026, and these are our main stories: Spain moves to classify certain futures products as CFDs for retail investors, IUX reports more than $1.5 trillion in monthly trading volume, and a closer look at why crypto still struggles to reach the mainstream.
Today’s Thursday, the 11th of June 2026, and these are our main stories: Spain moves to classify certain futures products as CFDs for retail investors, IUX reports more than $1.5 trillion in monthly trading volume, and a closer look at why crypto still struggles to reach the mainstream.
Today’s Thursday, the 11th of June 2026, and these are our main stories: Spain moves to classify certain futures products as CFDs for retail investors, IUX reports more than $1.5 trillion in monthly trading volume, and a closer look at why crypto still struggles to reach the mainstream.
Today’s Thursday, the 11th of June 2026, and these are our main stories: Spain moves to classify certain futures products as CFDs for retail investors, IUX reports more than $1.5 trillion in monthly trading volume, and a closer look at why crypto still struggles to reach the mainstream.
In this video, we review @AxiOfficialChannel , a multi-asset broker offering access to forex and CFD markets through MetaTrader 4, MetaTrader 5, the Axi Trading App, and copy trading solutions.
We examine the broker’s regulatory framework, platform offering, market coverage, and customer support structure. We also explore key features such as available trading instruments, swap-free account options, funding considerations, and multilingual support.
Watch the full video for a clear, fact-based overview of Axi’s products, trading tools, and overall broker offering.
#Axi #ForexBroker #CFDTrading #FinanceMagnates #Trading #BrokerReview #OnlineTrading
In this video, we review @AxiOfficialChannel , a multi-asset broker offering access to forex and CFD markets through MetaTrader 4, MetaTrader 5, the Axi Trading App, and copy trading solutions.
We examine the broker’s regulatory framework, platform offering, market coverage, and customer support structure. We also explore key features such as available trading instruments, swap-free account options, funding considerations, and multilingual support.
Watch the full video for a clear, fact-based overview of Axi’s products, trading tools, and overall broker offering.
#Axi #ForexBroker #CFDTrading #FinanceMagnates #Trading #BrokerReview #OnlineTrading
In this video, we review @AxiOfficialChannel , a multi-asset broker offering access to forex and CFD markets through MetaTrader 4, MetaTrader 5, the Axi Trading App, and copy trading solutions.
We examine the broker’s regulatory framework, platform offering, market coverage, and customer support structure. We also explore key features such as available trading instruments, swap-free account options, funding considerations, and multilingual support.
Watch the full video for a clear, fact-based overview of Axi’s products, trading tools, and overall broker offering.
#Axi #ForexBroker #CFDTrading #FinanceMagnates #Trading #BrokerReview #OnlineTrading
In this video, we review @AxiOfficialChannel , a multi-asset broker offering access to forex and CFD markets through MetaTrader 4, MetaTrader 5, the Axi Trading App, and copy trading solutions.
We examine the broker’s regulatory framework, platform offering, market coverage, and customer support structure. We also explore key features such as available trading instruments, swap-free account options, funding considerations, and multilingual support.
Watch the full video for a clear, fact-based overview of Axi’s products, trading tools, and overall broker offering.
#Axi #ForexBroker #CFDTrading #FinanceMagnates #Trading #BrokerReview #OnlineTrading
In this video, we review @AxiOfficialChannel , a multi-asset broker offering access to forex and CFD markets through MetaTrader 4, MetaTrader 5, the Axi Trading App, and copy trading solutions.
We examine the broker’s regulatory framework, platform offering, market coverage, and customer support structure. We also explore key features such as available trading instruments, swap-free account options, funding considerations, and multilingual support.
Watch the full video for a clear, fact-based overview of Axi’s products, trading tools, and overall broker offering.
#Axi #ForexBroker #CFDTrading #FinanceMagnates #Trading #BrokerReview #OnlineTrading
In this video, we review @AxiOfficialChannel , a multi-asset broker offering access to forex and CFD markets through MetaTrader 4, MetaTrader 5, the Axi Trading App, and copy trading solutions.
We examine the broker’s regulatory framework, platform offering, market coverage, and customer support structure. We also explore key features such as available trading instruments, swap-free account options, funding considerations, and multilingual support.
Watch the full video for a clear, fact-based overview of Axi’s products, trading tools, and overall broker offering.
#Axi #ForexBroker #CFDTrading #FinanceMagnates #Trading #BrokerReview #OnlineTrading
Multi-Asset or Die: The New Brokerage Playbook
Multi-Asset or Die: The New Brokerage Playbook
Multi-Asset or Die: The New Brokerage Playbook
Multi-Asset or Die: The New Brokerage Playbook
Multi-Asset or Die: The New Brokerage Playbook
Multi-Asset or Die: The New Brokerage Playbook
This panel will explore how firms are moving beyond CFDs into crypto, perpetuals, equities, and multi‑asset offerings, and the challenges they face across regulation, technology, liquidity, and risk management. It examines what is driving the shift, what it takes to execute it successfully, and how brokers can position themselves for the next phase of growth.
This panel will explore how firms are moving beyond CFDs into crypto, perpetuals, equities, and multi‑asset offerings, and the challenges they face across regulation, technology, liquidity, and risk management. It examines what is driving the shift, what it takes to execute it successfully, and how brokers can position themselves for the next phase of growth.
This panel will explore how firms are moving beyond CFDs into crypto, perpetuals, equities, and multi‑asset offerings, and the challenges they face across regulation, technology, liquidity, and risk management. It examines what is driving the shift, what it takes to execute it successfully, and how brokers can position themselves for the next phase of growth.
This panel will explore how firms are moving beyond CFDs into crypto, perpetuals, equities, and multi‑asset offerings, and the challenges they face across regulation, technology, liquidity, and risk management. It examines what is driving the shift, what it takes to execute it successfully, and how brokers can position themselves for the next phase of growth.
This panel will explore how firms are moving beyond CFDs into crypto, perpetuals, equities, and multi‑asset offerings, and the challenges they face across regulation, technology, liquidity, and risk management. It examines what is driving the shift, what it takes to execute it successfully, and how brokers can position themselves for the next phase of growth.
This panel will explore how firms are moving beyond CFDs into crypto, perpetuals, equities, and multi‑asset offerings, and the challenges they face across regulation, technology, liquidity, and risk management. It examines what is driving the shift, what it takes to execute it successfully, and how brokers can position themselves for the next phase of growth.
Beyond Reach? Retail Investor Acquisition Across APAC
Beyond Reach? Retail Investor Acquisition Across APAC
Beyond Reach? Retail Investor Acquisition Across APAC
Beyond Reach? Retail Investor Acquisition Across APAC
Beyond Reach? Retail Investor Acquisition Across APAC
Beyond Reach? Retail Investor Acquisition Across APAC
APAC accounts for two-thirds of global retail trading traffic, but with differences of language, regulation, and trader profile, the region's growth is ag great as complexity.
This session gathers CMOs, heads of acquisition, and IB relationship managers to examine what actually works, channel by channel, market by market.
Attendees will walk away with:
A clear view of which channels deliver funded, retained traders across Singapore, Japan, and Southeast Asia
Understanding of how to structure IB partnerships for LTV, not first deposit
Insight into what localization actually costs beyond the translation budget
Perspective on how ad restrictions, crypto promotion limits, and bundling rules differ across APAC jurisdictions
A read on whether the super-app model changes acquisition economics for retail investing platforms
APAC accounts for two-thirds of global retail trading traffic, but with differences of language, regulation, and trader profile, the region's growth is ag great as complexity.
This session gathers CMOs, heads of acquisition, and IB relationship managers to examine what actually works, channel by channel, market by market.
Attendees will walk away with:
A clear view of which channels deliver funded, retained traders across Singapore, Japan, and Southeast Asia
Understanding of how to structure IB partnerships for LTV, not first deposit
Insight into what localization actually costs beyond the translation budget
Perspective on how ad restrictions, crypto promotion limits, and bundling rules differ across APAC jurisdictions
A read on whether the super-app model changes acquisition economics for retail investing platforms
APAC accounts for two-thirds of global retail trading traffic, but with differences of language, regulation, and trader profile, the region's growth is ag great as complexity.
This session gathers CMOs, heads of acquisition, and IB relationship managers to examine what actually works, channel by channel, market by market.
Attendees will walk away with:
A clear view of which channels deliver funded, retained traders across Singapore, Japan, and Southeast Asia
Understanding of how to structure IB partnerships for LTV, not first deposit
Insight into what localization actually costs beyond the translation budget
Perspective on how ad restrictions, crypto promotion limits, and bundling rules differ across APAC jurisdictions
A read on whether the super-app model changes acquisition economics for retail investing platforms
APAC accounts for two-thirds of global retail trading traffic, but with differences of language, regulation, and trader profile, the region's growth is ag great as complexity.
This session gathers CMOs, heads of acquisition, and IB relationship managers to examine what actually works, channel by channel, market by market.
Attendees will walk away with:
A clear view of which channels deliver funded, retained traders across Singapore, Japan, and Southeast Asia
Understanding of how to structure IB partnerships for LTV, not first deposit
Insight into what localization actually costs beyond the translation budget
Perspective on how ad restrictions, crypto promotion limits, and bundling rules differ across APAC jurisdictions
A read on whether the super-app model changes acquisition economics for retail investing platforms
APAC accounts for two-thirds of global retail trading traffic, but with differences of language, regulation, and trader profile, the region's growth is ag great as complexity.
This session gathers CMOs, heads of acquisition, and IB relationship managers to examine what actually works, channel by channel, market by market.
Attendees will walk away with:
A clear view of which channels deliver funded, retained traders across Singapore, Japan, and Southeast Asia
Understanding of how to structure IB partnerships for LTV, not first deposit
Insight into what localization actually costs beyond the translation budget
Perspective on how ad restrictions, crypto promotion limits, and bundling rules differ across APAC jurisdictions
A read on whether the super-app model changes acquisition economics for retail investing platforms
APAC accounts for two-thirds of global retail trading traffic, but with differences of language, regulation, and trader profile, the region's growth is ag great as complexity.
This session gathers CMOs, heads of acquisition, and IB relationship managers to examine what actually works, channel by channel, market by market.
Attendees will walk away with:
A clear view of which channels deliver funded, retained traders across Singapore, Japan, and Southeast Asia
Understanding of how to structure IB partnerships for LTV, not first deposit
Insight into what localization actually costs beyond the translation budget
Perspective on how ad restrictions, crypto promotion limits, and bundling rules differ across APAC jurisdictions
A read on whether the super-app model changes acquisition economics for retail investing platforms